Want to see PL:SLV full AI Analyst Report?
SLV Stock Chart & Stats
zł46.50
--
Market closed
zł46.50
--
Day’s Range― - ―
52-Week Rangezł28.10 - zł49.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)40.05K
Market Cap
zł576.36M
Enterprise Valuezł721.53M
Total Cash (Recent Filing)zł19.89M
Total Debt (Recent Filing)zł167.93M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding18,355,474
10 Day Avg. Volume21,446
30 Day Avg. Volume40,050
Financial Highlights & Ratios
PEG Ratio-8.60
Price to Book (P/B)2.46
Price to Sales (P/S)2.18
P/FCF Ratio13.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.83
Revenue Forecast (FY)zł386.53M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue growth, even if slight, indicates resilience and potential for market expansion, supporting long-term business sustainability.
Cash Flow ImprovementStrong improvement in free cash flow enhances financial flexibility, enabling strategic investments and debt reduction, strengthening long-term stability.
Stable Balance SheetA stable balance sheet with a moderate debt-to-equity ratio suggests prudent financial management, supporting long-term operational and strategic initiatives.
Bears Say
Profitability DeclineDeclining profitability, indicated by negative net profit margins, could hinder reinvestment capabilities and long-term growth potential if not addressed.
Operational Efficiency ChallengesInefficiencies in cost management can erode margins and competitiveness, impacting the company's ability to sustain growth and profitability over time.
Negative Return On EquityNegative return on equity reflects poor shareholder returns, which could deter investment and affect the company's ability to raise capital in the future.
SLV FAQ
What was Selvita SA’s price range in the past 12 months?
Selvita SA lowest stock price was zł28.10 and its highest was zł49.40 in the past 12 months.
What is Selvita SA’s market cap?
Selvita SA’s market cap is zł576.36M.
When is Selvita SA’s upcoming earnings report date?
Selvita SA’s upcoming earnings report date is Sep 17, 2026 which is in 73 days.
How were Selvita SA’s earnings last quarter?
Currently, no data Available
Is Selvita SA overvalued?
According to Wall Street analysts Selvita SA’s price is currently Overvalued.
Does Selvita SA pay dividends?
Selvita SA does not currently pay dividends.
What is Selvita SA’s EPS estimate?
Selvita SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Selvita SA have?
Selvita SA has 18,355,474 shares outstanding.
What happened to Selvita SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Selvita SA?
Currently, no hedge funds are holding shares in PL:SLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Selvita SA
Selvita S.A., a contract research organization (CRO), provides its services across Poland, throughout Europe, in the United States, and to global clients. The company is structured around two main divisions: its core Contract Research Organization (CRO) offerings and Bioinformatics. Within its drug discovery portfolio, Selvita delivers a comprehensive suite of services including assay development and screening, expertise in medicinal and synthetic chemistry, advanced computer-aided drug design leveraging artificial intelligence, structural biology, in vitro and in vivo pharmacology studies, ADME/DMPK assessments, and general analytical testing. Furthermore, Selvita extends its capabilities to pharmaceutical services, encompassing drug testing and bioanalytical analysis. These services cover development and optimization processes, validation and transfer, stability studies, rigorous quality control, and assistance with regulatory compliance. The organization also engages in diverse research and development activities, such as process research, bespoke laboratory-scale synthesis of New Chemical Entities (NCEs), industrial chemistry solutions, and the creation of isotopically labeled compounds. Support for the agrochemical industry is also part of their R&D offerings. Moreover, Selvita delivers specialized bio-data science and sophisticated software solutions tailored for data-centric organizations within the life science and healthcare sectors. Established in 2007, Selvita S.A. maintains its headquarters in Krakow, Poland.
Technical Analysis
Pure Biologics SA
―
Ryvu Therapeutics SA
―
Celon Pharma SA
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―
Options Prices
Currently, No data available
---